ustekinumab sold brand name stelara among others monoclonal antibody medication developed janssen pharmaceuticals treatment crohns disease ulcerative colitis plaque psoriasis psoriatic targeting ustekinumab approved treat crohns disease united states israel australia european union ulcerative colitis us eu people responded traditional found effective multiple administered either intravenous infusion subcutaneous antibody targets subunit human interleukin interleukin naturally occurring proteins regulate immune system immunemediated inflammatory ustekinumab used treat includes psoriatic arthritis affects indicated treatment adult adolescent patients years older moderate severe plaque psoriasis ps candidates phototherapy systemic therapy adults active psoriatic arthritis psa alone combination also used treat moderately severely active crohns disease moderately severely active ulcerative european union ustekinumab approved treat moderate severe plaque psoriasis adults children age six years whose condition improved use systemic wholebody psoriasis treatments ciclosporin methotrexate puva psoralen ultraviolet active psoriatic arthritis moderately severely active crohns disease moderately severely active ulcerative colitis according information provided centocor maker one medication based ustekinumab version ustekinumab associated several types serious adverse effects include increased risk infection tuberculosis increased risk certain types cancer immunosuppressant drugs like ciclosporin brain swelling posterior reversible encephalopathy syndrome risk pharmaceutical company also reports serious allergic reaction possible side effect common side effects upper respiratory infection headache clinical trials shown subcutaneous ustekinumab generally well tolerated treatmentemergent adverse events mild unknown medication safe pregnancy ustekinumab designed interfere triggering bodys inflammatory response suppression certain cytokines specifically blocks interleukin help activate certain tcells binds subunit subsequently bind january five nihlisted research studies involving cnto multinational basis including three phase ii two phase iii trials three studies focused patients psoriasis one psoriatic arthritis one multiple sclerosiscitation needed december biologic license application bla us food drug administration fda filed centocor janssencilag international collaborator submitted marketing authorization application maa european medicines agency ema november committee medicinal products human use chmp ema adopted positive opinion ustekinumab treatment moderate severe plaque psoriasis adults failed respond systemic since ustekinumab approved canada european union united states treat moderate severe plaque september us food drug administration fda approved use ustekinumab treatment psoriatic arthritiscitation needed december health canada approved use ustekinumab treatment chronic moderate severe plaque psoriasis adults candidates phototherapy systemic fda approved ustekinumab september treatment adults moderate severe plaque fda approved ustekinumab september treatment crohns since september ustekinumab available au pharmaceutical benefits scheme treatment severe crohns disease european commission approved use ustekinumab adults moderately severely active ulcerative october fda approved use ustekinumab adults moderately severely active ulcerative october wezlana approved medical use united november committee medicinal products human use european medicines agency adopted positive opinion recommending granting marketing authorization medicinal product uzpruvo intended treatment plaque psoriasis including pediatric plaque psoriatic arthritis crohns disease applicant medicinal product stada arzneimittel uzpruvo biosimilar medicinal immune activation dostarlimab ibalizumab httpsenwikipediaorgwikiustekinumab